Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial.

Sydney Chi-Wai TangKam Wa ChanDennis K M IpDesmond Y H YapMaggie K M MaMaggie M Y MokGary C W ChanSidney TamKar Neng Lai

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)

Aliskiren neither conferred additional renoprotective benefit nor increased adverse events, except for more hyperkalemia in nondiabetic CKD patients.

Keyphrases

chronic kidney disease
end stage renal disease
peritoneal dialysis

ejection fraction
newly diagnosed
type diabetes

prognostic factors
patient reported outcomes
patient reported

diabetic nephropathy
angiotensin converting enzyme